SCHEMBL2747465

SCHEMBL2747465

Oc1ncc2ccccc2c1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.48
GPR3 P46089 1/20 0.48
MAOA P21397 1/20 0.38
CYP1A2 P05177 2/20 0.38
POLB P06746 1/20 0.36
NPC1 O15118 1/20 0.36
PTPN22 Q9Y2R2 1/20 0.35
TRPM4 Q8TD43 1/20 0.35
ALDH1A1 P00352 2/20 0.35
HSD17B10 Q99714 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
MAPK1 P28482 1/20 0.35
MAPKAPK2 P49137 1/20 0.35
PARP1 P09874 1/20 0.35
PRKCI P41743 1/20 0.35
PDE4B Q07343 1/20 0.35
EGFR P00533 1/20 0.35
KDR P35968 1/20 0.35
ERN1 O75460 1/20 0.35
CYP2A6 P11509 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30790223 0.80 KDM4E (0.50) KDM4EGPR3MAOACYP1A2PTPN22
SCHEMBL9125784 0.80 KDM4E (0.50) KDM4EGPR3MAOACYP1A2PTPN22
SCHEMBL16836457 0.77 KDM4E (0.47) KDM4EGPR3MAOACYP1A2NPC1
SCHEMBL7315366 0.77 POLB (0.50) KDM4EGPR3CYP1A2POLBNPC1
SCHEMBL2747868 0.77 KDM4E (0.47) KDM4EGPR3MAOACYP1A2ALDH1A1
SCHEMBL16144709 0.77 GPR3 (0.47) KDM4EGPR3MAOACYP1A2NPC1
SCHEMBL7435560 0.77 KDM4E (0.47) KDM4EGPR3MAOACYP1A2POLB
SCHEMBL4105404 0.76 KDM4E (0.42) KDM4EGPR3MAOACYP1A2ALDH1A1
SCHEMBL14311585 0.72 KDM4E (0.48) KDM4EGPR3CYP1A2POLBALDH1A1
SCHEMBL22721580 0.72 KDM4E (0.42) KDM4EGPR3MAOAPOLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178668-B2 2-aminopyridine kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-05-15 US disclosed
EP-2265270-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2010-12-29 EP disclosed
WO-2009099982-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2009-08-13 WO disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 KDM4E 1371/4885GPR3 2089/4885MAOA 3748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.